Journal
EXPERT REVIEWS IN MOLECULAR MEDICINE
Volume 20, Issue -, Pages -Publisher
CAMBRIDGE UNIV PRESS
DOI: 10.1017/erm.2018.5
Keywords
Cell-free circulating DNA; cell-free circulating tumour DNA; diagnosis; liquid biopsy; ovarian cancer; prognosis; therapy monitoring
Funding
- Norte Portugal Regional Operational Programme (NORTE 2020), under the PORTUGAL 2020 Partnership Agreement, through the European Regional Development Fund (ERDF)
- [NORTE-01-0145-FEDER-000027]
Ask authors/readers for more resources
Circulating cell-free DNA (cfDNA) consists of small fragments of DNA that circulate freely in the bloodstream. In cancer patients, a fraction of cfDNA is derived from tumour cells, therefore containing the same genetic and epigenetic alterations, and is termed circulating cell-free tumour DNA. The potential use of cfDNA, the so-called 'liquid biopsy', as a non-invasive cancer biomarker has recently received a lot of attention. The present review will focus on studies concerning the potential clinical applications of cfDNA in ovarian cancer patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
